PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer

J. Duch*, D. Fuster, M. Munoz, P. L. Fernandez, P. Paredes, M. Fontanillas, K. Skaltsa, B. Domenech, F. Lomena, F. Pons

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Aim. The aim of this paper was to prospectively evaluate FDG PET/CT in the assessment of metabolic response to neoadjuvant chemotherapy and correlation with tumor cellularity in locally advanced breast cancer.

Methods. Images were acquired with a PET/CT scanner in 50 patients at baseline and after completion of treatment, just before surgery. All findings were confirmed by histopathological analysis. PET/CT quantification (SUVmax) at baseline and after finishing neoadjuvant chemotherapy (4 cycles of epirubicin + cyclophosphamide +/- taxanes) were compared using RECIST criteria and Miller & Payne (M&P) scale.

Results. Baseline mean tumor size was 4.4 +/- 1.6 cm. Thirty eight patients were considered responders and 12 nonresponders. According to M&P scale, 10 patients had good prognosis (grades 4-5) and 40 patients had bad prognosis (grades 1-3). All patients with grade 5 M&P had no significant postchemotherapy FDG uptake. Patients with bad prognosis had lower SUVmax variation (Delta SUVmax) than patients with good prognosis (60.7% vs. 80.5%, P=0.0016). Delta SUVmax was lower in nonresponders than in partial responders according to RECIST criteria (38.9% vs. 67.6%, p45 to 82) showed an overall accuracy of 78% (Weighted Kappa=0.74).

Conclusion. PET/CT is useful to monitor response to neoadjuvant chemotherapy in locally advanced breast cancer. Delta SUVmax on PET/CT correlates with tumor cellularity after completion of neoadjuvant chemotherapy.

Original languageEnglish
Pages (from-to)291-298
Number of pages8
JournalQ J Nucl Med Imaging
Volume56
Issue number3
Publication statusPublished - Jun 2012

Keywords

  • Breast neoplasms
  • Positron-emission tomography
  • X-ray, computed tomography
  • POSITRON-EMISSION-TOMOGRAPHY
  • CELL LUNG-CANCER
  • PREOPERATIVE CHEMOTHERAPY
  • FDG-PET
  • PATHOLOGICAL RESPONSE
  • F-18-FDG PET
  • TUMOR RESPONSE
  • HISTOPATHOLOGY
  • MAMMOGRAPHY
  • PREDICTION

Cite this